MEG
LGND icon

Millstone Evans Group’s Ligand Pharmaceuticals LGND Stock Holding History

Millstone Evans Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.6K Hold
133
– – 0.02% 446
2025
Q4 		$25.1K Hold
133
– – 0.01% 440
2025
Q3 		$23.6K Hold
133
– – 0.02% 434
2025
Q2 		$15.1K Hold
133
– – 0.01% 478
2025
Q1 		$14K Hold
133
– – 0.01% 486
2024
Q4 		$14.3K Buy
+133
New +$15K 0.01% 459

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Millstone Evans Group's LGND Position: Q1 2026 in Review

Millstone Evans Group held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 133 shares worth $26.6K. The position accounts for 0.02% of the portfolio, ranked #446.

Millstone Evans Group first reported a position in LGND in Q4 2024 and has held it in 6 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Millstone Evans Group held 133 shares of Ligand Pharmaceuticals worth $26.6K as of Q1 2026.
  • Millstone Evans Group left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
  • Ligand Pharmaceuticals made up 0.02% of Millstone Evans Group's portfolio in Q1 2026, its #446 holding.
  • Millstone Evans Group first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Millstone Evans Group's 13F filing for Q1 2026, filed 30 Apr 2026.